{"Title": ["KOD Dazzles, GLMD On Watch, DRIO Turns Heads\u2026", "Galmed Pharmaceuticals (GLMD) Reports Q4 Loss, Misses Revenue Estimates", "Pre-Market Earnings Report for March 13, 2019 : NRE, VRA, DQ, EXPR, ESTE, GLMD, TRVN, GECC, SKIS, AAC, CBK", "Intercept (ICPT) Benefits from Ocaliva's Recovery in 2018", "Novan Announces Top-Line Data From Mid-Stage Molluscum Study", "Galmed Pharmaceuticals (GLMD) in Focus: Stock Moves 6.2% Higher", "Galmed Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?", "Galmed Pharmaceuticals (GLMD) Reports Q3 Loss, Tops Revenue Estimates", "KOD Dazzles, GLMD On Watch, DRIO Turns Heads\u2026", "10 Killer Stocks to Buy That No One Knows About", "10 Killer Stocks to Buy That No One Knows About", "Intercept (ICPT) Gains on Solid Q2 Results, Ocaliva Recovers", "Medical-Drugs Stock Outlook: No Respite from Near-Term Pain", "7 Health Care Stocks to Buy for Robust Returns", "What's in Store for Universal Health's (UHS) Q2 Earnings?", "What's in the Cards for HCA Healthcare (HCA) in Q2 Earnings?", "Intercept (ICPT) Gains on Earnings and Revenue Beat in Q3", "This Is the Most Undervalued NASH Drug Stock, and Wall Street Is Ignoring It", "3 Biotech Stocks That Soared This Week: Are They Buys?", "3 NASH Stocks That Could Soar in the Second Half of 2018", "Are These Red-Hot NASH Stocks Still a Buy?", "NASH Space in Focus as Galmed (GLMD) Posts Positive Data", "Galmed (GLMD) Soars on Positive NASH Data on Aramchol", "Why Galmed Pharmaceuticals Ltd Stock Is Going Gangbusters Today", "Here's Why Galmed Pharmaceuticals Ltd. Was Up 19% Today and 33% for the Week", "Close Update: Stocks Trim Losses As Wall Street Pivots From Geopolitics to Central Banks", "Pre-Market Earnings Report for March 13, 2018 : HDS, DKS, GDS, DSW, EPZM, NRE, ATRS, MLNT, ARLZ, GNMX, TSQ, GLMD", "3 Reasons Why Galmed Pharmaceuticals (GLMD) is a Great Momentum Stock", "Galmed Pharmaceuticals (GLMD) Catches Eye: Stock Gains 15.7%", "Pre-Market Earnings Report for May 15, 2017 : SPNS, SPP, WLB, VBLT, BDSI, SORL, MARK, ALDX, GLMD, NTWK, REED, DGLY", "Nonalcoholic Steatohepatitis (NASH): What's The Market Opportunity And Who Are The Major Players?", "5 Biotech Stocks to Watch as Interest in NASH Increases", "Why Galmed Pharmaceuticals Ltd. Stock Is Skyrocketing Today", "Pre-Market Earnings Report for May 16, 2016 : VRTU, PWE, ADHD, GLMD, CELP, CLSN, SORL, FES", "Wednesday Sector Leaders: Oil & Gas Exploration & Production, Drugs", "Galmed Pharmaceuticals (GLMD) Jumps: Stock Rises 7.9%", "Health Care Sector Update for 03/22/2016: ANAC, GLMD", "Galmed Pharmaceuticals (GLMD) Jumps: Stock Up 21.8%", "Galmed Pharmaceuticals (GLMD) Jumps: Stock Rises 13.7%", "Health Care Sector Update for 08/13/2015: ICPT, EBIO, GLMD", "Biotech ETFs in Focus on Tobira Therapeutics' Massive Gain", "Galmed Inks Deal to Develop Non-Invasive Diagnostic Tool - Analyst Blog", "Intercept Pharmaceuticals Reveals Phase III OCA Study Plan - Analyst Blog", "Health Care Sector Update for 04/15/2015: LXRX, GLMD, NAVB", "NASH/HIV biotech Tobira Therapeutics revives IPO plans; updates financials and underwriters", "Sector Update: Health Care Stocks Sag Throughout Session; Galmed Pharma Jumps After FDA Puts Liver Drug on Fast Track to Market", "Sector Update: Health Care", "Immunotherapy biotech Tobira Therapeutics postpones $60 million IPO", "Should You Sell Galmed Pharmaceuticals (GLMD) Before Earnings? - Tale of the Tape", "Biotechs post better returns this week before an IPO tech wave", "6 US IPOs planned for the week of Mar 10", "Liver disease biotech Galmed sets terms for $31 million IPO", "Galmed Pharmaceuticals prices upsized IPO at $13.50, within the range"], "Elapsed Time": ["DEC 2, 2019", "MAR 13, 2019", "MAR 12, 2019", "DEC 28, 2018", "DEC 11, 2018", "NOV 20, 2018", "NOV 13, 2018", "NOV 5, 2018", "DEC 2, 2019", "OCT 12, 2018", "AUG 6, 2018", "AUG 3, 2018", "AUG 2, 2018", "JUL 27, 2018", "JUL 20, 2018", "JUL 20, 2018", "NOV 1, 2018", "JUN 26, 2018", "JUN 16, 2018", "JUN 15, 2018", "JUN 14, 2018", "JUN 14, 2018", "JUN 13, 2018", "JUN 12, 2018", "JUL 13, 2018", "JUN 12, 2018", "MAR 12, 2018", "SEP 5, 2017", "JUL 25, 2017", "MAY 12, 2017", "SEP 29, 2016", "SEP 22, 2016", "JUN 12, 2018", "MAY 13, 2016", "APR 6, 2016", "MAR 29, 2016", "MAR 22, 2016", "JAN 21, 2016", "OCT 9, 2015", "AUG 13, 2015", "SEP 21, 2016", "JUL 9, 2015", "MAY 20, 2015", "APR 15, 2015", "OCT 22, 2014", "SEP 23, 2014", "SEP 23, 2014", "AUG 7, 2014", "JUL 23, 2015", "MAR 13, 2014", "MAR 10, 2014", "FEB 28, 2014", "MAR 13, 2014"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/kod-dazzles-glmd-on-watch-drio-turns-heads...-2019-12-02", "https://www.nasdaq.com/articles/galmed-pharmaceuticals-glmd-reports-q4-loss-misses-revenue-estimates-2019-03-13", "https://www.nasdaq.com/articles/pre-market-earnings-report-march-13-2019-nre-vra-dq-expr-este-glmd-trvn-gecc-skis-aac-cbk", "https://www.nasdaq.com/articles/intercept-icpt-benefits-from-ocalivas-recovery-in-2018-2018-12-28", "https://www.nasdaq.com/articles/novan-announces-top-line-data-from-mid-stage-molluscum-study-2018-12-11", "https://www.nasdaq.com/articles/galmed-pharmaceuticals-glmd-in-focus%3A-stock-moves-6.2-higher-2018-11-20", "https://www.nasdaq.com/articles/galmed-pharmaceuticals-sees-hammer-chart-pattern%3A-time-to-buy-2018-11-13", "https://www.nasdaq.com/articles/galmed-pharmaceuticals-glmd-reports-q3-loss-tops-revenue-estimates-2018-11-05", "https://www.nasdaq.com/articles/kod-dazzles-glmd-on-watch-drio-turns-heads...-2019-12-02", "https://www.nasdaq.com/articles/10-killer-stocks-to-buy-that-no-one-knows-about-2018-10-12", "https://www.nasdaq.com/articles/10-killer-stocks-to-buy-that-no-one-knows-about-2018-08-06", "https://www.nasdaq.com/articles/intercept-icpt-gains-on-solid-q2-results-ocaliva-recovers-2018-08-03", "https://www.nasdaq.com/articles/medical-drugs-stock-outlook%3A-no-respite-from-near-term-pain-2018-08-02", "https://www.nasdaq.com/articles/7-health-care-stocks-buy-robust-returns-2018-07-27", "https://www.nasdaq.com/articles/whats-in-store-for-universal-healths-uhs-q2-earnings-2018-07-20", "https://www.nasdaq.com/articles/whats-in-the-cards-for-hca-healthcare-hca-in-q2-earnings-2018-07-20", "https://www.nasdaq.com/articles/intercept-icpt-gains-on-earnings-and-revenue-beat-in-q3-2018-11-01", "https://www.nasdaq.com/articles/most-undervalued-nash-drug-stock-and-wall-street-ignoring-it-2018-06-26", "https://www.nasdaq.com/articles/3-biotech-stocks-soared-week-are-they-buys-2018-06-16", "https://www.nasdaq.com/articles/3-nash-stocks-could-soar-second-half-2018-2018-06-15", "https://www.nasdaq.com/articles/are-these-red-hot-nash-stocks-still-buy-2018-06-14", "https://www.nasdaq.com/articles/nash-space-focus-galmed-glmd-posts-positive-data-2018-06-14", "https://www.nasdaq.com/articles/galmed-glmd-soars-on-positive-nash-data-on-aramchol-2018-06-13", "https://www.nasdaq.com/articles/why-galmed-pharmaceuticals-ltd-stock-going-gangbusters-today-2018-06-12", "https://www.nasdaq.com/articles/heres-why-galmed-pharmaceuticals-ltd-was-19-today-and-33-week-2018-07-13", "https://www.nasdaq.com/articles/close-update-stocks-trim-losses-wall-street-pivots-geopolitics-central-banks-2018-06-12", "https://www.nasdaq.com/articles/pre-market-earnings-report-march-13-2018-hds-dks-gds-dsw-epzm-nre-atrs-mlnt-arlz-gnmx-tsq", "https://www.nasdaq.com/articles/3-reasons-why-galmed-pharmaceuticals-glmd-is-a-great-momentum-stock-2017-09-05", "https://www.nasdaq.com/articles/galmed-pharmaceuticals-glmd-catches-eye%3A-stock-gains-15.7-2017-07-25", "https://www.nasdaq.com/articles/pre-market-earnings-report-may-15-2017-spns-spp-wlb-vblt-bdsi-sorl-mark-aldx-glmd-ntwk", "https://www.nasdaq.com/articles/nonalcoholic-steatohepatitis-nash-whats-market-opportunity-and-who-are-major-players-2016", "https://www.nasdaq.com/articles/5-biotech-stocks-watch-interest-nash-increases-2016-09-22", "https://www.nasdaq.com/articles/why-galmed-pharmaceuticals-ltd-stock-skyrocketing-today-2018-06-12", "https://www.nasdaq.com/articles/pre-market-earnings-report-may-16-2016-vrtu-pwe-adhd-glmd-celp-clsn-sorl-fes-2016-05-13", "https://www.nasdaq.com/articles/wednesday-sector-leaders-oil-gas-exploration-production-drugs-2016-04-06", "https://www.nasdaq.com/articles/galmed-pharmaceuticals-glmd-jumps%3A-stock-rises-7.9-2016-03-29", "https://www.nasdaq.com/articles/health-care-sector-update-03222016-anac-glmd-2016-03-22", "https://www.nasdaq.com/articles/galmed-pharmaceuticals-glmd-jumps%3A-stock-up-21.8-2016-01-21", "https://www.nasdaq.com/articles/galmed-pharmaceuticals-glmd-jumps%3A-stock-rises-13.7-2015-10-09", "https://www.nasdaq.com/articles/health-care-sector-update-08132015-icpt-ebio-glmd-2015-08-13", "https://www.nasdaq.com/articles/biotech-etfs-focus-tobira-therapeutics-massive-gain-2016-09-21", "https://www.nasdaq.com/articles/galmed-inks-deal-to-develop-non-invasive-diagnostic-tool-analyst-blog-2015-07-09", "https://www.nasdaq.com/articles/intercept-pharmaceuticals-reveals-phase-iii-oca-study-plan-analyst-blog-2015-05-20", "https://www.nasdaq.com/articles/health-care-sector-update-04152015-lxrx-glmd-navb-2015-04-15", "https://www.nasdaq.com/articles/nashhiv-biotech-tobira-therapeutics-revives-ipo-plans-updates-financials-and-underwriters", "https://www.nasdaq.com/articles/sector-update-health-care-stocks-sag-throughout-session-galmed-pharma-jumps-after-fda-puts", "https://www.nasdaq.com/articles/sector-update-health-care-2014-09-23-0", "https://www.nasdaq.com/articles/immunotherapy-biotech-tobira-therapeutics-postpones-60-million-ipo-2014-08-07", "https://www.nasdaq.com/articles/should-you-sell-galmed-pharmaceuticals-glmd-before-earnings-tale-of-the-tape-2015-07-23", "https://www.nasdaq.com/articles/biotechs-post-better-returns-week-ipo-tech-wave-2014-03-13", "https://www.nasdaq.com/articles/6-us-ipos-planned-week-mar-10-2014-03-10", "https://www.nasdaq.com/articles/liver-disease-biotech-galmed-sets-terms-31-million-ipo-2014-02-28", "https://www.nasdaq.com/articles/galmed-pharmaceuticals-prices-upsized-ipo-1350-within-range-2014-03-13"], "Content": []}